Research Article

Active Ingredients of Epimedii Folium and Ligustri Lucidi Fructus Balanced GR/HSP90 to Improve the Sensitivity of Asthmatic Rats to Budesonide

Xiufeng Tang, Xiaoxi Li, Honglei Nian, Yan Yang, Yuheng Chen, Xiujuan Wang, Liping Xu, Xinwei Yang, and Renhui Liu

Beijing Key Lab of TCM Collateral Disease Theory Research, School of Traditional Chinese Medicine, Capital Medical University, No. 10 Xitoutiao, Youanmenwai, Fengtai District, Beijing 100069, China

Correspondence should be addressed to Renhui Liu; gzblrh45@ccmu.edu.cn

Received 6 January 2017; Revised 2 April 2017; Accepted 12 April 2017; Published 11 May 2017

Copyright © 2017 Xiufeng Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study aimed to investigate the possible molecular mechanisms of active ingredients of Epimedii Folium (EF) and Ligustri Lucidi Fructus (LLF) combined with Budesonide (Bun) in asthmatic rats. Rats were divided into 5 groups, including normal group, asthma model group, Bun group, group of active ingredients of EL and LLF (EL), and group of coadministration of Bun with EL (Bun&EL). The asthmatic model was prepared by ovalbumin sensitizing and challenging. Lymphocyte apoptosis, GR protein and binding, and the protein and mRNA of GRα, GRβ, and HSP90 were tested. The results showed that Bun&EL markedly increased lymphocyte apoptosis, GR and HSP90 protein, and GR binding in BALF and enhanced the expressions of GRα and HSP90 and the ratio of GRα to GRβ or to HSP90 both in protein and in mRNA levels in lung, while decrease occurred in GRβ mRNA and the ratio of GRβ to HSP90 compared with asthma or Bun group. Moreover, there was a significant correlation between GRα and GRβ in protein level, or between GRα and HSP90 both in protein and in mRNA levels. EL may effectively enhance the sensitivity of asthmatic rats to Bun via balancing GR/HSP90. And these findings will be beneficial for the treatment of asthma in the future.

1. Introduction

Asthma is one of the most serious worldwide public health problems that affects all age groups [1] and is characterized by chronic airway inflammation [2]. Glucocorticoids (GCs), which have powerful anti-inflammatory effects, are thought to be the first choice for the prevention and treatment of asthma, especially the application of inhaled GCs, playing anti-inflammatory effects and reducing the systemic side effects of GCs in a certain extent [3, 4]. But some asthma patients with treatment of inhaled GCs at conventional doses may experience no curative effects. When inhaled GCs are administered at high doses, or in long-term using, a series of side effects will be produced, such as growth stunting in children, hormone dependence, hormone resistance, and hypothalamic-pituitary-adrenal (HPA) axis dysfunction [5–7]. In particular, in the face of the occurrence of GC resistance, the current treatment would cost very much due to the lack of effective alternative therapy [8].

How to increase the sensitivity of GC actions in the airway of asthma patients and reduce its adverse reactions has a great significance for the treatment of asthma. GCs mediate their effects via binding to glucocorticoid receptor (GR). GR depends on the heat shock protein 90 (HSP90) molecular chaperone for in vivo function. HSP90 is required for GR to bind ligand and become active and can promote GR-GC binding capacity [9, 10]. So the expression of GR and HSP90 is closely related to the pharmacological effects of GCs.

The traditional Chinese formula, combined Epimedii Folium (EF) and Ligustri Lucidi Fructus (LLF), following the TCM theories and clinical experience, has been used to treat asthmatic patients in China for three decades [11]. Preclinical studies reported that combined EF and LLF (EF&LLF, ET) was able to decrease airway inflammation and airway
hyperresponsiveness, adjust the disequilibrium of Th1/Th2, and protect HPA axis in asthmatic rats [12]. In our previous researches, we demonstrated that the decoction of combined EF and LLF (EL) in combination with dexamethasone (Dex) had a better anti-inflammatory effect on the ovalbumin-(OVA-) induced asthmatic rats and could prevent the inhibition of HPA axis and loss of bone mass compared with only using Dex [13, 14]. The effects of EL combined with inhaled GCs on asthma are not clear.

The active ingredients of EL are mainly flavonoids and iridoid, including icariin and oleanolic acid. Icariin possesses extensive therapeutic effects such as protecting neurons from injury, promoting growth of neuronal synapse, regulating of nuclear receptors, and improving sexual dysfunction and bone morphogenesis, as well as anti-inflammation, antitumor, and antidepressant functions [15]. Oleanolic acid is able to protect against chemically induced liver injury and has the effects of anti-inflammatory and antihyperlipidemic properties, antitumor-promotion, inhibition of toxicant activation, and the enhancement of the body defense systems [16]. Based on the above understanding about GR/HSP90 in the efficacy of GC, we supposed that the active ingredients of EL could improve GR/HSP90 function to achieve the increased sensitivity of asthma rats to GCs. Therefore, we investigated the effects of coadministration of active ingredients of EL and Budesonide (Bun) on GR, GR isoforms and HSP90, and the evaluation of the correlation between GR and HSP90 in the lung tissue of asthma rats.

2. Material and Methods

2.1. Preparation of Active Ingredients. Epimedi Foliurn (the dried leaf of Epimediium brevicornu Maxim) and Ligustri Lucidi Fructus (the dried mature seed of Ligustrium lucidum Ait.) were purchased from Beijing Tongrentang Pharmaceutical Co. Ltd., China. The two herbs were seriously authenticated and standardized through their marker compounds according to the Chinese Pharmacopoeia (2015) and stored in a dry and sealed container at 4°C to prevent herbs from moisture and moth.

Preparation of active ingredients of EF and LLF, including flavonoids and iridoids, was performed according to the methods described before [17]. And the extraction process of the combined active ingredients has been protected by the Chinese patent (20140037992.5). EF (1000 g) was extracted three times with 90% ethanol (10,000 mL) for 3 h, 2 h, and 2 h at 70°C in a reflux apparatus. The extracts were mixed, filtered, and concentrated under reduced pressure, until recovery to no alcohol precipitation. Using AB-8 macroporous resin, the extracts were washed with distilled water and then with 75% ethanol after the water solution was discarded. The steamed extracts are total iridoid of LLF. The yield of Ligustri Lucidi Fructus extracts was 5%. Based on the phytochemical test (Pharmacopoeia of the People’s Republic of China, 2010 Edition), the content of LLF extracts was more than 80% calculated by oleanolic acid and rutin. The combination of active ingredients of EF and LLF (EL) was mixed at a ratio of 2 to 3, equivalent to the raw herbs ratio of 4 to 3 according to clinical practice. The combined active fractions were dissolved in distilled water at appropriate concentrations.

2.2. Animals. 40 male Sprague-Dawley rats, weighing 120 to 130 g with the average age of four or five weeks, were purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China). The experiment complied with the Animal Management Rule of the Ministry of Public Health, China, and the experimental protocol was approved by the Animal Care Committee of Capital Medical University, Beijing, China. All the animals were cared for in the Experimental Animal Center of Capital Medical University. During the whole experiment, the animals were housed in stainless cages (three rats per cage) at conventional controlled conditions (temperature of 23 ± 2°C, relative humidity of 50 ± 10%, and 12-hour light-dark cycle). They were allowed free access to the standard laboratory food and tap water.

2.3. Experimental Protocol. After acclimatization for 7 days, the rats were randomly assigned into 5 groups (n = 8 per group): normal control group, asthma model group, Bun group, EL group, and group of coadministration of Bun with EL (Bun&EL).

OVA sensitization and challenge protocols were performed according to the methods of Yang et al. [18] with certain modifications as described below. All the rats with the exception of those in the normal control group were actively sensitized with an intraperitoneal (i.p.) injection and subcutaneous injection of 1 mg OVA (Grade II, Sigma-Aldrich, St. Louis, MO, USA) and 100 μg aluminum hydroxide in 1 mL sterile physiological saline. After seven days, the same procedure was repeated. After another seven days, the OVA-sensitized rats were exposed to 1% aerosolized OVA (1g OVA in 100 mL sterile physiological saline in an ultrasonic nebulizer) for 30 min once a day. Three weeks later, the OVA-sensitized rats were challenged twice a week and treated once a day. Rats in the Bun and Bun&EL groups were exposed to Bun suspension (AstraZeneca Pty Ltd., New South Wales, Australia) for inhalation (1 mg Bun suspension in 50 mL sterile physiological saline in an ultrasonic nebulizer) for 30 min. Rats in the EL and Bun&EL groups were administered with the active ingredients of EL at the dose of 100 mg/kg body weight. At the same time, the rats in the normal control group and asthma group were given the same volume of distilled water.

On the 64th day, all the rats were anesthetized with 25% ethyl carbamate (4 mL/kg, i.p.) 24 h after the last OVA exposure. Blood samples were collected by abdominal aortic
puncture. Lungs were lavaged 3 times with 3 mL, 3 mL, and 4 mL ice-cold saline using a tracheal cannula and a 5 mL polyethylene syringe. The cell-debris pellets of bronchoalveolar lavage fluid (BALF) samples were collected after centrifugation (500 rpm, 5 min, and 4°C). Lymphocytes were separated from blood and BALF samples with assay of rat lymphocyte separation solution (Tianjin Hao Yang Biological Manufacturing Co., Ltd., Tianjin, China) and then resuspended with 1 mL of 4% paraformaldehyde-phosphate buffer solution.

2.4. TUNEL Assay for Lymphocyte Apoptosis. Lymphocytes apoptosis in blood and BALF was determined using the TUNEL assay (MBL, Inc., Nagoya, Japan) for flow cytometry (FCM) according to manufacturer's instruction. A FACSAria flow cytometer (BD, Lake Franklin, NJ, USA) was used to determine lymphocyte apoptosis level through mean fluorescence intensity (MFI).

2.5. GR Protein in BALF Lymphocyte by FCM. The samples of 300 μL lymphocyte resuspension from BALF were washed with PBS twice and refixed in 100 μL of 4% buffered paraformaldehyde for 30 min at 4°C. Nonspecific binding site was blocked with 5% normal goat serum containing permeabilisation buffer for 30 min. The lymphocytes were then incubated with 100 μL permeabilisation buffer containing 50 μL anti-GR mAb (Abcam, Cambridge, UK; 1:100) for 60 min, washed twice with permeabilisation buffer, and then incubated with 100 μL permeabilisation buffer containing 50 μL of goat anti-mouse IgG-FITC (Caltag, Burlingame, CA, USA; 1:100) for 60 min. After extensive washing with permeabilisation buffer to remove unbound secondary antibodies, the lymphocytes were resuspended in 500 μL fixation buffer. Lymphocyte samples were run on a FACSAria FCM. The relative quantity of GR protein (mean fluorescence) was expressed as MFI.

2.6. GR Binding in BALF Lymphocyte by FCM. The samples of 300 μL lymphocyte resuspension from BALF were washed with PBS and resuspended in 100 μL PBS containing 2 × 10^{-5} M PE-Dex (Molecular Probe, Invitrogen, Carlsbad, CA, USA) for 60 min at 37°C in the dark with gentle mixing every 10 min. As controls, another tube was prepared adding a 500-fold excess amount of unlabelled Dex (Sigma, St. Louis, MO, USA) 10 min before PE-Dex. Finally, the lymphocytes were washed twice and resuspended in 300 μL fixation buffer. Lymphocyte samples were run on a FACSAria FCM. The relative quantity of GR binding (mean fluorescence) was expressed as MFI.

2.7. Protein of GRα, GRβ, and HSP90 in Lung by Immunohistochemistry (IHC). GRα, GRβ, and HSP90 were identified in paraffin-embedded sections of the lung tissue by IHC staining with anti-GRα (Abcam, Cambridge, UK), GRβ (Biorbyt, Cambridge, UK), or HSP90 antibody (Abcam, Cambridge, UK) overnight at 4°C at a concentration of 1:100 (GRα and HSP90) or 1:50 (GRβ) followed by standard biotin-streptavidin-peroxidase immunostaining using a streptavidin-peroxidase kit (Zhongshan Goldenbridge Biotechnology, Beijing, China) following the instructions provided by the manufacturer. Staining was completed by incubation with diaminobenzidine chromogen solution at room temperature. All measurements were performed with the Nikon ECLIPSE 80i biomicroscope and NIS-Elements BR 3.2 image analysis system (Nikon, Japanese). Three random images within a lung sample were taken and further analyzed by using zoomed-in field at 400x magnification. We measured the total optical density (IOD) and the positive area of GRα, GRβ, and HSP90-positive cells under each examined field and calculated the average number as the final result of this sample.

2.8. HSP90 Protein in BALF by Immunocytochemistry (ICC). To further confirm HSP90 expression in airway, we select ICC analysis to detect HSP90 protein in BALF cell residue. After fixation by cold acetone for 10 min, BALF cytopsins were incubated with 3% hydrogen peroxide for 10 min. After being blocked with normal goat serum for 20 min, the samples were incubated with anti-HSP90 antibody (Abcam, Cambridge, UK) at a concentration of 1:50 for 1 h at 37°C. Polink-2 Plus Polymer HRP Detection Systems were used and then developed with diaminobenzidine (DAB) kit (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China). All measurements were performed with the Nikon ECLIPSE 80i biomicroscope and NIS-Elements BR 3.2 image analysis system (Nikon, Japanese).

2.9. Protein of GRα, GRβ, and HSP90 by Western Blotting (WB) Analysis. The total protein was extracted from 50 mg lung tissue using RIPA lysis buffer. Concentration of the protein was quantified by quantitative bromochloroacetate (BCA) protein kit (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China). The protein was mixed with loading buffer and boiled at 95°C for 5 min to make it denatured. Equal amounts of protein (40 μg per lane) were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred into 0.45 μm polyvinylidene fluoride (PVDF) membranes. After blocking with 5% nonfat-dried milk at room temperature for 2 h, membranes were incubated with primary antibodies: rabbit polyclonal to HSP90 antibody (Abcam, Cambridge, UK; 1:5000), rabbit polyclonal to GRα antibody (Abcam, Cambridge, UK; 1:2000), rabbit polyclonal to GRβ antibody (Biorbyt, Cambridge, UK; 1:2000), and mouse monoclonal to β-actin antibody (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China; 1:2000) overnight at 4°C. Membranes were detected with horseradish peroxidase-labeled goat anti-rabbit IgG (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China; 1:20000) or goat anti-mouse IgG (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China; 1:40000) as the secondary antibody for 1 h. The protein band was visualized by an electrochemiluminescent (ECL) reagent and exposed to X-film. β-Actin was used for normalization. The sumdensity of each protein band was measured by Image software (National Institutes of Health, USA).

2.10. mRNA of GR, GRα, GRβ, and HSP90 by Quantitative Real-Time PCR (qPCR). Total RNA was isolated from the lung tissue using TRIzol reagent (Life Technologies, Carlsbad, CA, USA).
CA, USA) according to the manufacturer’s recommendations. Following purification with an RNeasy kit (Qiagen, Valencia, CA, USA), M-MLV reverse transcription (Promega, Madison, USA) was used to synthesize complementary DNA (cDNA). The qPCR amplification was performed using the SYBR-green detection of PCR products in real time with an ABI-7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The primers used in the qPCR analysis are presented in Table 1. The PCR program was performed for 40 cycles with each cycle consisting of 5 min of predenaturation at 94°C, 15 s of denaturation at 94°C, and 30 s of annealing at 60°C. Gene expression was quantified by means of the comparative Ct method (\( \Delta\Delta \)Ct) and the relative quantification (RQ) was calculated as \( 2^{-\Delta\Delta C_t} \). Relative mRNA levels of GR, GRα, GRβ, and HSP90 were examined and normalized to 18S mRNA expression in each sample. The melting curves for each PCR were generated to ensure the purity of the amplification product. A no-template negative control was included in each experiment.

2.11. Statistical Analysis. Results of all measurements were presented as means ± standard deviation (SD). The data analysis was performed using the SPSS 13.0 (SPSS Inc., Chicago, USA). All of the data were tested for normality using the Kolmogorov-Smirnov test and passed. A one-way analysis of variance (ANOVA) was performed to determine whether there were statistically significant differences (\( P < 0.05 \)) among the experimental groups. The least significant difference (LSD) test when the variances are equal or Tamhane’s T2 test when the variances are not equal was used for comparisons between individual groups and to determine which means differed statistically significantly (\( P < 0.05 \)). Pearson correlation analysis was used for detecting the correlation of data.

3. Results

3.1. Effects of Coadministration of Bun and EL on Lymphocyte Apoptosis. Both anti-inflammatory effect and side effect of GCs were related to inducing apoptosis in autologous mixed lymphocytes [19, 20]. So the level of lymphocyte apoptosis could indicate the sensitivity of Bun to asthmatic inflammation. In this study, we used TUNEL assay to detect lymphocyte apoptosis in BALF and peripheral blood by FCM.

The level of lymphocyte apoptosis in BALF, which was significantly lower in the asthma model group than in the control group, was shown in Figure 1(a) (\( P = 0.032 \)). Treatment with Bun, EL, and Bun&EL significantly increased BALF lymphocyte apoptosis compared with those of the asthma group (\( P = 0.010, P = 0.000, \) and \( P = 0.000 \)). In addition, significant difference in lymphocyte apoptosis in BALF was found between the Bun group and the Bun&EL group (\( P = 0.006 \)). These results indicated the coadministration of Bun and EL could prevent the inhibition of BALF lymphocyte apoptosis in asthmatic rats and led to a synergistic upregulation.

3.2. Effects of Bun and EL on GR. Lymphocytes and GRs are the best candidates for researching the cellular and molecular targets of GCs. The sensitivity of GRs in lymphocytes may account, in part, for the immunosuppressive efficacy of GCs [21]. Abnormalities of GR seem to be related to steroid resistance, that is, the lower sensitivity of anti-inflammatory effects of GCs [22]. In this study, FCM was used to assess GR expression and binding capacity in BALF lymphocyte, and qPCR was used to detect GR mRNA level in lung tissue.

Figure 2(a) showed that there were no significant differences in GR protein expression of BALF lymphocyte between the control and asthma groups (\( P = 0.1881 \)). GR protein in BALF lymphocyte greatly increased following administration of EL or Bun&EL versus asthma or Bun group (versus asthma group: \( P = 0.000 \) and \( P = 0.001 \); versus Bun group: \( P = 0.006 \) and \( P = 0.015 \)).

As shown in Figure 2(b), GR binding in BALF lymphocyte was significantly decreased after modeling (\( P = 0.036 \)), which signified the inhibition of binding capacity between GC and GR. Following repeated Bun administration, GR binding in BALF lymphocyte was still in a state of suppression in contrast with control group (\( P = 0.043 \)). However, significant increase in GR binding of BALF lymphocyte was noticed in the Bun&EL group compared with the asthma or Bun group (\( P = 0.028 \) or \( P = 0.033 \)). It was induced that coadministration of Bun and EL could markedly raise the binding capacity between GC and GR.

As shown in Figure 2(c), GR mRNA in lung tissue was dramatically decreased in asthma rats versus the control group (\( P = 0.020 \)). Following repeated Bun administration, GR mRNA was still in a state of suppression in contrast with the control group (\( P = 0.013 \)). However, GR mRNA expression was significantly increased in the EL and Bun&EL groups compared with the asthma or Bun group (versus asthma group: \( P = 0.003 \) and \( P = 0.002 \); versus Bun group: \( P = 0.002 \) and \( P = 0.000 \)). We inferred that coadministration of Bun and EL could markedly raise GR mRNA expression in lung.

| Primer | Forward primer | Reverse primer |
|--------|----------------|----------------|
| GR     | GCCCTGGCTTTGAGACATGTCAT | CATGAGGTAGAGACATTGTC |
| GRα    | GGGACAGACGCTTGAGTGCAT | CCATGCCACGTAAGTGTAG |
| GRβ    | GCCCTGAGCTTGAAGTACTCT | CCCATGTTCTGCTTGGTTT |
| HSP90  | CCTGAGAGACCCCCCG | TTGTAGACATGACAGAGGACC |
| 18S    | CCGTACATGAACTGCAGA | GATAATAGCAGGGTGATCCC |

Table 1: Primers used for qPCR analysis.
Figure 1: Effects of Bun and EL on lymphocyte apoptosis in blood and BALF. The levels of lymphocyte apoptosis in BALF and peripheral blood were detected by FCM with TUNEL assay in control, asthma, Bun, EL, and Bun&EL groups. (a) Summarized data of MFI of lymphocyte apoptosis in BALF. (b) Summarized data of MFI of lymphocyte apoptosis in peripheral blood. Representative FCM photographs of lymphocyte apoptosis in BALF (c) and peripheral blood (d), including the single parameter histogram and the dot plots of SSC versus FSC, were viewed in control, asthma, Bun, EL, and Bun&EL groups. Values are expressed as mean ± SD. n = 7 in control, asthma, Bun, EL, and Bun&EL group, respectively; *P < 0.05 versus control group; #P < 0.05 and ##P < 0.01 versus asthma group; #*P < 0.01 versus Bun group.
Figure 2: Effects of Bun and EL on GR. GR protein and binding capacity in BALF were detected by FCM in control, asthma, Bun, EL, and Bun&EL groups. (a) Summarized data of MFI of GR protein in BALF. (b) Summarized data of MFI of GR binding capacity in BALF. (c) The mRNA expression of GR was measured by qPCR analysis with 18S as an internal control. Representative FCM photographs of GR protein (d) or GR binding capacity (e) in BALF, including the single parameter histogram and the dot plots of SSC versus FSC, were viewed in control, asthma, Bun, EL, and Bun&EL groups. Values are expressed as mean ± SD. *n = 6 in control, asthma, Bun, EL, and Bun&EL group, respectively. *P < 0.05 versus control group; ^P < 0.05 and ^^P < 0.01 versus asthma group; *P < 0.05 and ^^^P < 0.01 versus Bun group. *P < 0.05 versus control group.
3.3. Effects of Bun and EL on GRα. GCs act through the intracellular GR signals into changes in gene expression [23]. One single GR gene gives rise to two main GR products, namely, GRα and GRβ, which are subject to translational and post-translational modifications. GRα is expressed in virtually all human cells and tissues, including respiratory epithelial cells, and is downregulated by GC at least in vitro. GRα is ubiquitously expressed and is responsible for the induction and repression of target genes [24]. GRα expression was positively correlated with the anti-inflammatory effect of GC.

As shown in Figures 3(a) and 3(b), positive area and integral optical density (IOD) of GRα protein expression detected by IHC were significantly decreased in asthma and Bun groups versus the control group (positive area: both $P = 0.000$; IOD: $P = 0.045$ and $P = 0.032$). However, GRα positive area and IOD were remarkably increased in EL and Bun&EL groups compared with the asthma or Bun group (all $P < 0.01$).

GRα protein expression was further confirmed by WB analysis (Figure 3(c)). GRα protein was downregulated in asthma and Bun groups versus the control group ($P = 0.000$ and $P = 0.003$). There was a significant increase in GRα protein in Bun, EL, and Bun&EL groups compared with the asthma group ($P = 0.027$, $P = 0.000$, and $P = 0.000$). The coadministration of Bun and EL significantly increased GRα protein expression versus the Bun group ($P = 0.039$).

GRα mRNA expression was detected by qPCR analysis (Figure 3(d)). GRα mRNA expression was markedly decreased in asthma and Bun groups versus the control group (both $P = 0.000$). Compared with asthma or Bun group, significant increase was noticed in GRα mRNA in the EL or Bun&EL group ($P = 0.000$).

3.4. Effects of Bun and EL on GRβ. GRβ acts as a dominant-negative inhibitor of GRα-mediated transactivation and transrepression in certain cell types. Increased expression of GRβ, which competes with and thus inhibits activated GRα, has been suggested that GRβ could cause steroid resistance [25]. Very low GRβ mRNA levels have been detected in a number of cells and tissues, which often contradict GRβ protein data. An association between GC insensitivity and increased GRβ expression has been reported in asthma and in vitro, certain proinflammatory cytokines upregulate GRβ expression [26]. In this study, the protein and mRNA expressions of GRβ in the lung tissue were tested by IHC, WB, and qPCR analysis, and an altered ratio in the expression of GRα and GRβ was calculated.

As shown in Figures 4(a), 4(b), and 4(c), there was no significant change in GRβ protein expression in lung between the control and asthma groups. GRβ mRNA (Figure 4(d)) was upregulated in the asthma and Bun groups versus the control group ($P = 0.021$ and $P = 0.007$). However, there was a significant decrease in GRβ mRNA expressions in the EL and Bun&EL groups compared with the asthma or Bun group (all $P < 0.05$).

The protein ratio tested by WB (Figure 5(a)) or mRNA ratio (Figure 5(c)) of GRα to GRβ was markedly reduced in the asthma and Bun groups versus the control group (both $P < 0.01$). Compared to the asthma group, GRα/GRβ protein ratios were significantly increased in the EL and Bun&EL groups (both $P < 0.01$). Compared to the asthma or Bun group, GRα/GRβ mRNA ratio was significantly increased in the EL and Bun&EL groups (all $P < 0.01$). In addition, there was a significant correlation between GRα and GRβ in protein level (Figure 5(b)).

3.5. Effects of Bun and EL on HSP90. HSP90 associates selectively with unliganded GR, and the proper folding of GR depends on direct interactions with the chaperone, HSP90 [27]. Although an association with HSP90 presumably masks the GR nuclear localization signal sequence, the recent demonstration of the coimport of GR and HSP90 into nuclei has led to the hypothesis that HSP90 facilitates GR interactions with the nuclear transport machinery [28].

In this report, we examined HSP90 protein expressions in the lung tissue by IHC and WB. As shown in Figures 6(a), 6(b), and 6(c), HSP90 protein was significantly decreased in the asthma and Bun groups versus the control group (all $P < 0.01$). And, compared to the asthma or Bun group, HP90 protein levels were significantly increased in the EL and Bun&EL groups ($P < 0.05$ or $P < 0.01$). To further determine the effects of Bun and EL on HSP90 protein expression in airway, we used ICC method to detect this expression in BALF. As shown in Figures 6(d) and 6(e), HSP90 protein expression in BALF was significantly decreased in the asthma and Bun groups versus the control group ($P < 0.05$ or $P < 0.01$). Compared with the asthma or Bun group, HSP90 protein was significantly increased in the EL and Bun&EL groups (all $P < 0.01$).

HSP90 mRNA in lung was detected by qPCR methods (Figure 6(f)). HSP90 mRNA was markedly decreased in the asthma and Bun groups versus the control group (both $P < 0.05$). Compared with the asthma or Bun group, HSP90 mRNA was significantly increased in the EL and Bun&EL groups (all $P < 0.01$).

3.6. Effects of Bun and EL on the Relation between GR Isoforms and HSP90. The ligand binding activity of GR is related to the changes of HSP90 after all. To evaluate the correlation between GR and HSP90 on the asthmatic rat treated with EL combined with Bun, we calculated the ratio of GR isoforms (including GRα and GRβ) to HSP90 and evaluated the association between ligand binding activity of GR and HSP90.

The ratios of GRα to HSP90 in the levels of protein (Figure 7(a)) and mRNA (Figure 7(c)) were markedly reduced in the asthma group versus the control group ($P < 0.05$ and $P < 0.01$). Compared to the asthma group, the ratios were significantly increased in Bun&EL groups ($P < 0.01$ and $P < 0.05$). And compared to the Bun group, GRα/HSP90 in the mRNA level was significantly increased in EL or Bun&EL group (both $P < 0.01$). In addition, there was a significant correlation between GRα and HSP90 in protein level ($r = 0.7102$, $P = 0.000$; Figure 7(b)) or in mRNA level ($r = 0.6704$, $P = 0.000$; Figure 7(d)).

Figures 8(a) and 8(c) showed that the ratios of GRβ to HSP90 in protein and mRNA levels were markedly higher in the asthma and Bun groups than that in the control group (all
Figure 3: Effects of Bun and EL on GRα. GRα protein and mRNA expressions in lung tissues were detected by IHC, WB, and qPCR. (a) Summarized data of positive area of GRα protein expression in lung tissues measured by IHC. (b) Summarized data of IOD of GRα protein expression in lung tissues measured by IHC. (c) Summarized data of sum density of GRα protein expression in lung tissues measured by WB, normalized to β-actin. (d) The mRNA expression of GRα was measured by qPCR analysis with 18S as an internal control. (e) Representative IHC photographs of GRα were viewed at a magnification of 400x in control, asthma, Bun, EL, and Bun&EL groups. (f) Representative WB photographs of GRα were viewed, and β-actin was used for normalization in control, asthma, Bun, EL, and Bun&EL groups. Values are expressed as mean ± SD. n = 7 (a, b), n = 5 (c), or n = 6 (d). *P < 0.05 and **P < 0.01 versus control group; ##P < 0.01 versus asthma group; \( \cdot \)P < 0.05 and \( \cdot \cdot \cdot \)P < 0.01 versus Bun group. *P < 0.05.
Figure 4: Effects of Bun and EL on GRβ expression. GRβ protein and mRNA expressions in lung tissues were detected by IHC, WB, and qPCR. (a) Summarized data of positive area of GRβ protein expression in lung tissues measured by IHC. (b) Summarized data of IOD of GRβ protein expression in lung tissues measured by IHC. (c) Summarized data of sum density of GRβ protein expression in lung tissues measured by WB, normalized to β-actin. (d) The mRNA expression of GRβ was measured by qPCR analysis with 18S as an internal control. (e) Representative IHC photographs of GRβ were viewed at a magnification of 400x in control, asthma, Bun, EL, and Bun&EL groups. (f) Representative WB photographs of GRβ were viewed, and β-actin was used for normalization in control, asthma, Bun, EL, and Bun&EL groups. Values are expressed as mean ± SD. n = 7 (a, b), n = 5 (c), and n = 6 (d). ∗P < 0.05 and ∗∗P < 0.01 versus control group; #P < 0.05 versus asthma group; % P < 0.05 versus Bun group.
Asthma Bun EL control

![Graph](image)

**Figure 5:** Effects of Bun and EL on correlation between GRα and GRβ. (a) The ratio of GRα to GRβ was calculated in the level of relative protein measured by WB, normalized to β-actin. (b) The correlation between GRα and GRβ was analyzed in the level of relative protein measured by qPCR with 18S as an internal control. (c) The ratio of GRα to GRβ was calculated in the level of relative mRNA expression measured by qPCR with 18S as an internal control. (d) The correlation between GRα and GRβ was analyzed in the level of relative mRNA expression measured by qPCR with 18S as an internal control. Values are expressed as mean ± SD. n = 5 (a), n = 6 (c), n = 25 (b), or n = 30 (d).

P < 0.01). In the protein level, GRβ/HSP90 ratio was lower in the EL and Bun&EL groups versus the Bun group (both P < 0.05). In the mRNA level, GRβ/HSP90 ratio was decreased in the EL and Bun&EL groups compared to the asthma or Bun group (all P < 0.01). Figures 8(b) and 8(d) showed that there was no significant correlation between GRβ and HSP90 in the protein or mRNA level.

### 4. Discussion

Airway inflammation is considered to be the basic pathological change and one of the key pathological mechanisms of repeated attacks of asthma [29, 30]. GCs remain the cornerstone of asthma management because of the most effective anti-inflammatory effect. But it is inevitable that adverse reactions happen with administration of GC with large dose or long protocol. We think that improving the sensitivity of GC to airway inflammation in asthma and reducing the dosage of GC medication will effectively prevent the occurrence of its adverse reactions.

In China, traditional Chinese medicine (TCM) has been widely used to treat asthma with its unique advantages for thousands of years. According to TCM theories, kidney governs qi reception, which means that kidney plays important roles in respiratory function. Because kidney deficiency is the main internal disease causes of asthma, the treatment of asthma in remission stage follows the basic strengthening-kidney rules [31]. ET (Yinyanghuo) and LLF (Nvzhenzi) were documented as replenishing kidney-yang and kidney-yin herbs, respectively. Combined ET and LLF (EL), a little formula designed following the TCM theories and clinical experience, has been used to treat asthmatic patients in China for three decades [11]. Preclinical studies reported that ET treatment was able to decrease airway inflammation and airway hyperresponsiveness, adjust the disequilibrium of Th1/Th2, and protect HPA axis [12].
Figure 6: Continued.
Figure 6: Effects of Bun and EL on HSP90. HSP90 protein and mRNA expressions in lung tissues were measured by IHC, WB, and qPCR. And HSP90 protein expression in BALF was detected by ICC. (a) Summarized data of positive area of HSP90 protein expression in lung tissues measured by IHC. (b) Summarized data of IOD of HSP90 protein expression in lung tissues measured by IHC. (c) Summarized data of sum density of HSP90 protein expression in lung tissues measured by WB, normalized to β-actin. (d) Summarized data of positive area of HSP90 protein expression in BALF measured by ICC. (e) Summarized data of IOD of HSP90 protein expression in BALF measured by ICC. (f) The mRNA expression of HSP90 was measured by qPCR analysis with 18S as an internal control. (g) Representative IHC photographs of HSP90 were viewed at a magnification of 400x in control, asthma, Bun, EL, and Bun&EL groups. (h) Representative ICC photographs of HSP90 were viewed at a magnification of 400x in control, asthma, Bun, EL, and Bun&EL groups. (i) Representative WB photographs of GRβ were viewed, and β-actin was used for normalization in control, asthma, Bun, EL, and Bun&EL groups. Values are expressed as mean ± SD. n = 8 (a, b) and n = 6 (c, d, e, f). *P < 0.05 and **P < 0.01 versus control group; *P < 0.05 and **P < 0.01 versus asthma group; *P < 0.05 and **P < 0.01 versus Bun group.

Figure 7: Effects of Bun and EL on correlation between GRα and HSP90. (a) The ratio of GRα to HSP90 was calculated in the level of relative protein measured by WB, normalized to β-actin. (b) The correlation between GRα and HSP90 was analyzed in the level of relative protein measured by WB, normalized to β-actin. (c) The ratio of GRα to HSP90 was calculated in the level of relative mRNA expression measured by qPCR with 18S as an internal control. (d) The correlation between GRα and HSP90 was analyzed in the level of relative mRNA expression measured by qPCR with 18S as an internal control. Values are expressed as mean ± SD. n = 5 (a), n = 6 (c), n = 25 (b), and n = 30 (d). **P < 0.01 versus control group. *P < 0.05 and **P < 0.01 versus asthma group; *P < 0.05 and **P < 0.01 versus Bun group. *P < 0.05 versus control group.
According to TCM theories, the use of GCs in clinical practice is able to injure kidney function and leads to kidney deficiency [32]. And the suppression of the HPA axis and the decrease of GR content or GR binding caused by administration of GC were proved to play key roles in pathogenesis of kidney deficiency syndrome [33, 34]. So many TCM doctors take the methods of tonifying kidney to prevent and treat the side effects of GC [35, 36]. In our previous researches, we demonstrated that the decoction of EL in combination with dexamethasone (Dex) had a better anti-inflammatory effect, increased the mRNA and protein expression of GR in lung, and prevented the inhibition of HPA axis and loss of bone mass in the asthmatic rats, compared with only using Dex [13, 14]. It is induced that EL could increase the sensitivity and decrease the side effects of GC. However, the underlying molecular mechanism of EL combined with inhaled GCs is not yet well understood.

Alterations in the GR expression are one of the potential mechanisms that would explain GC insensitivity. Abnormalities in GR binding to GCs have been described in the lymphocytes of patients with GC-resistant asthma or in asthma in general [37]. GR expression is downregulated by GC administration in bronchial epithelial cells, and GR binding activity and GC responsiveness are depressed by proinflammatory stimuli in asthma [38, 39]. Although GCs therapy could suppresses allergen-induced airway inflammation, epithelial cell shedding is not corrected and asthma cannot be cured completely [40, 41]. Reduction of GR mRNA and protein expression in the lungs of mice exposed to allergen has been reported [42]. These findings of decreased expression of GR in asthma patients or allergic mice suggest that an overall reduction in GR may compromise asthma immune response [43]. According to the results, it could be observed that the levels of GR binding capability in BALF lymphocytes and GR
mRNA expression in lung tissues were markedly decreased in the OVA-induced asthmatic rats, suggesting impaired GR function in asthma. Treatment with EL and coadministration of Bun and EL could increase GR binding capability and GR mRNA expression in airway. This increase might improve GC sensitivity when used for the treatment of asthma. GR gene expresses 2 splicing isoforms, that is, GRα and GRβ [44]. GRβ with a truncated ligand binding domain does not bind GCs and was found to be a dominant-negative inhibitor of the classic GRα [45]. Increased GRβ expression has been reported in bronchial asthma [46]. Certain proinflammatory cytokines upregulate GRβ expression. And an association between increased GRβ expression and GC insensitivity has been confirmed in asthma [26]. There is growing evidence that high expression of GRβ could be responsible for the development of insensitivity to GCs in a variety of inflammatory disorders [47]. It has been proposed that GC resistance could result from the imbalance between GRα and GRβ, though little is known whether the GRα/GRβ ratio could determine the level of GC responsiveness [48]. Additionally, it has been shown that GRβ did not interfere with GR-mediated transrepression and GRβ excess seems to overcome its inhibitory action [49]. As shown in this study, the mRNA expression of GRβ increased, while the mRNA and protein expressions of GRα were downregulated in the OVA-induced asthmatic rats and those treated with Bun, which was in accord with the results of GR binding capability and mRNA expression in airway. Both administration of EL and coadministration of Bun and EL could increase GRα protein and mRNA expression, decrease GRβ mRNA expression, and correct GRα/GRβ ratio in the protein or mRNA level. These findings indicate that EL could promote the pharmacological actions of GRα-mediated GC and inhibit GRβ-mediated insensitivity of GC, suggesting that the coadministration of Bun and ET is beneficial to improve anti-inflammatory effects of GCs and prevent GC resistance.

The ligand binding activity of GR is related to the changes of HSP90. The inactive form of GR in the cytoplasm is bound to HSP90. This interaction facilitates binding of GC to GR and depends on the relative amounts of the interacting components, GR and HSP90 [50]. HSP90 content is maybe related to the GR sensitivity to GCs. HSP90 does not inhibit GR function solely by steric interference; rather, HSP90 seems to facilitate the subsequent response of apoGR to the hormonal signal (Vamvakopoulos, 1993). In this report, we found that the protein and mRNA expressions of HSP90 in airway were significantly decreased after modeling; besides, there were decreased GRα/HSP90 ratio and increased GRβ/HSP90 ratio in the protein or mRNA level. Both administration of EL and coadministration of Bun and EL could increase HSP90 expression and modulate the ratio of GRα to HSP90 or GRβ to HSP90. We could infer from our results that the regulation mechanisms of EL on GC sensitivity may be associated with HSP90 expression and the balance between GR and HSP90.

5. Conclusions

In this study, we have found that EL combined with Bun had superior effects in increasing BALF lymphocyte apoptosis and GR binding capacity, upregulating the protein and mRNA expressions of GR, GRα, and HSP90, improving GRα/GRβ ratio and GRα/HSP90 ratio in protein or mRNA level, and inhibiting GRβ expression and GRβ/HSP90 ratio in the mRNA level. Moreover, there was a significant correlation between GRα and GRβ in the protein level or between GRα and HSP90 both in the protein and in mRNA levels. Our results demonstrated that EL could effectively raise the sensitivity of Bun via balancing GR/HSP90. These findings will be beneficial for the treatment of asthma in the future.

**Abbreviations**

- BALF: Bronchoalveolar lavage fluid
- Bun: Budesonide
- FC: Flow cytometry
- FITC: Fluorescein isothiocyanate
- GC: Glucocorticoid
- GR: Glucocorticoid receptor
- EF: Epimedi Foli fum
- EL: Epimedi Foli fum and Ligustri Lucidi Fructus
- LLF: Ligustri Lucidi Fructus
- HPA: Hypothalamic-pituitary-adrenal
- HSP90: Heat shock protein 90
- IHC: Immunohistochemistry
- ICC: Immunocytochemistry
- IOD: Integral optical density
- i.p.: Intraperitoneal injection
- MFI: Mean fluorescence intensity
- OVA: Ovalbumin
- PE: Phycoerythin
- qPCR: quantitative real-time PCR
- SD: Standard deviation
- TUNEL: Tdt-dUTP terminal nick-end labeling
- WB: Western blotting

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Authors’ Contributions**

X. Tang and X. Li equally contributed to this work.

**Acknowledgments**

This study was supported by Natural Science Foundation of China (Grant nos. 81373814 and 81673993), the Development of High-Caliber Talents Project of Beijing Municipal Institutions (Grant no. CIT&TD201504097), and the Planned Project on Beijing Traditional Chinese Medicine inheritance of "3 + 3 Programme" of the Beijing Chinese Medicine Administration Bureau (Grant no. 2012-SZ-C-42).

**References**

[1] R. Agarwal and D. Gupta, "Severe asthma and fungi: current evidence," *Medical Mycology*, vol. 49, Supplement 1, pp. S150–S157, 2011.
Evidence-Based Complementary and Alternative Medicine

[2] R. A. Covar, “Pivotal efficacy trials of inhaled corticosteroids in asthma,” *Annals of Allergy, Asthma & Immunology*, vol. 117, no. 6, pp. 582–588, 2016.

[3] P. J. Barnes, “Glucocorticosteroids: current and future directions,” *British Journal of Pharmacology*, vol. 163, no. 1, pp. 29–43, 2011.

[4] P. Zhang, L. Fang, H. Wu, P. Ding, Q. Shen, and R. Liu, “Down-regulation of GSR expression and inhibition of its nuclear translocation by hypoxia,” *Life Sciences*, vol. 146, pp. 92–99, 2016.

[5] E. W. Zöller, C. Lombard, U. Galal, E. Hough, E. Irusen, and E. Weinberg, “Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids - more common than expected?” *Journal of Pediatric Endocrinology and Metabolism*, vol. 24, no. 7–8, pp. 529–534, 2011.

[6] H. Jiang, X. Chi, X. Zhang, and J. Wang, “Increased serum VDBP as a risk predictor for steroid resistance in asthma patients,” *Respiratory Medicine*, vol. 114, pp. II–116, 2016.

[7] K. N. Priftis, A. Papadimitriou, M. B. Anthracopoulos, A. Fretzayas, and G. P. Chrousos, “Endocrine-immune interactions in adrenal function of asthmatic children on inhaled corticosteroids,” *NeuroImmunoModulation*, vol. 16, no. 5, pp. 333–339, 2009.

[8] D. Reddy and F. F. Little, “Glucocorticoid-resistant asthma: more than meets the eye,” *Journal of Asthma*, vol. 50, no. 10, pp. 1036–1044, 2013.

[9] I. Petta, L. Dejager, M. Ballegeer et al., “The interaction of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases,” *Microbiology and Molecular Biology Reviews*, vol. 80, no. 2, pp. 495–522, 2016.

[10] E. Kirschke, D. Goswami, D. Southworth, P. R. Griffin, and D. A. Agard, “Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles,” *Cell*, vol. 157, no. 7, pp. 1685–1697, 2014.

[11] R. Liu and X. Guo, “Experimental study of Yinyanghuo (Herba epimedi) / Nu zenzi (Fructus ligustriulici) on disequilibrium of TH1/ TH2 in astmatic rat,” *Chinese Archives of Traditional Chinese Medicine*, vol. 27, no. 11, pp. 2288–2291, 2009.

[12] R. Liu, J. Zheng, Y. Yuan, and X. Guo, “Adjustment effects of Herba Epimedi, Fructus Ligustriulici on NO/ET, HPA axis in astmatic rats,” *Zhongguo Zhongyao Zazhi*, vol. 35, no. 12, pp. 1590–1593, 2010.

[13] R. Liu, L. Xu, X. Wang, J. Yang, P. Wang, and L. Pan, “Experimental study on effect of combination of epimediol folium/ Ligustri Lucidi Fructus and dexamethasone on astmatic rats,” *Zhongguo Zhongyao Zazhi*, vol. 37, no. 10, pp. 1497–1499, 2012.

[14] R. Liu, X. Wang, W. Zhang, Y. Yuan, and P. Wang, “Effects of combination of Herba Epimedi, Ligustrum lucidum and dexamethasone on Hpa axis and Gr of astmatic model in rats,” *Zhonghua Yi Yi Yao Za Zhi*, vol. 28, no. 11, pp. 3215–3219, 2013.

[15] Y. Chen, J.-H. Huang, Y. Ning, and Z.-Y. Shen, “Icariin and its pharmaceutical efficacy: research progress of molecular mechanisms,” *Journal of Chinese Integrative Medicine*, vol. 9, no. 11, pp. 1179–1184, 2011.

[16] J. Liu, “Pharmacology of oleanolic acid and ursolic acid,” *Journal of Ethnopharmacology*, vol. 49, no. 2, pp. 57–68, 1995.

[17] R.-H. Liu, X. Kang, L.-P. Xu et al., “Effects of the combined extracts of Herba Epimedi and Fructus Ligustri Lucidi on bone mineral content and bone turnover in osteoporotic rats,” *BMC Complementary and Alternative Medicine*, vol. 15, no. 1, article 112, 2015.

[18] Y.-G. Yang, W.-M. Tian, H. Zhang, M. Li, and Y. Shang, “Nerve growth factor exacerbates allergic lung inflammation and airway remodeling in a rat model of chronic asthma,” *Experimental and Therapeutic Medicine*, vol. 6, no. 5, pp. 1251–1258, 2013.

[19] M. J. Olness, Y. Kotliarov, A. Biancotto et al., “Corrigendum: effects of systemically administered hydrocortisone on the human immune,” *Scientific Reports*, vol. 6, Article ID 23002, 2016.

[20] C. A. Longui and C. D. C. Faria, “Evaluation of glucocorticoid sensitivity and its potential clinical applicability,” *Hormone Research*, vol. 71, no. 6, pp. 305–309, 2009.

[21] C. D. C. Faria and C. A. Longui, “Molecular aspects of glucocorticoid sensitivity,” *Arquivos Brasileiros de Endocrinologia e Metabologia*, vol. 50, no. 6, pp. 983–995, 2006.

[22] Y. J. Cho and K. E. Lee, “Decreased glucocorticoid binding affinity to glucocorticoid receptor is important in the poor response to steroid therapy of older-aged patients with severe bronchial asthma,” *Allergy and Asthma Proceedings*, vol. 24, no. 5, pp. 353–358, 2003.

[23] M. M. Reilly, C. Pantoja, X. Hu, Y. Chinenov, and I. Rogatsky, “The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immune-suppression,” *The EMBO Journal*, vol. 25, no. 1, pp. 108–117, 2006.

[24] L. Pujols, J. Mullol, and C. Picado, “Glucocorticoid receptor in human respiratory epithelial cells,” *NeuroImmunoModulation*, vol. 16, no. 5, pp. 290–299, 2009.

[25] C. A. Butler, S. McQuaid, C. C. Taggart et al., “Glucocorticoid receptor β and histone deacetylase 1 and 2 expression in the Airways of severe asthma,” *Thorax*, vol. 67, no. 5, pp. 392–398, 2012.

[26] L. Pujols, J. Mullol, and C. Picado, “Alpha and beta glucocorticoid receptors: relevance in airway diseases,” *Current Allergy and Asthma Reports*, vol. 7, no. 2, pp. 93–99, 2007.

[27] X. Qian, Y. Zhu, and W. Xu, “The effects of heat shock protein 90 and glucocorticoid receptor on apoptosis in T lymphocytes from asthmatic patients,” *Zhonghua Yi Xue Za Zhi*, vol. 81, no. 24, pp. 1496–1499, 2001.

[28] J. Yang and D. B. DeFranco, “Assessment of glucocorticoid receptor-heat shock protein 90 interactions in vivo during nucleocytoplasmic trafficking,” *Molecular Endocrinology*, vol. 10, no. 1, pp. 3–13, 1996.

[29] E. D. Bateman, S. S. Hurd, P. J. Barnes et al., “Global strategy for asthma management and prevention: GINA executive summary,” *European Respiratory Journal*, vol. 31, no. 1, pp. 143–178, 2008.

[30] A. F. Behndig, N. Larsson, J. L. Brown et al., “Proinflammatory doses of diesel exhaust in healthy subjects fail to elicit equivalent or augmented airway inflammation in subjects with asthma,” *Thorax*, vol. 66, no. 1, pp. 12–19, 2011.

[31] B. Wu, J. Yu, Y. Wang, Y. Yang, and Y. Shi, “Effect of Chinese herbs for Tonifying Shen on balance of Th1/Th2 in children with asthma in remission stage,” *Zhongguo Zhong Xi Yi Jie He Za Zhi*, vol. 27, no. 2, pp. 120–122, 2007.

[32] P. Wang, L.-P. Xu, X.-H. Jin, J. Yang, R.-H. Liu, and X.-J. Wang, “Effects of a glucocorticoid on development of kidney deficiency syndrome in a rat model of asthma,” *Journal of Chinese Integrative Medicine*, vol. 8, no. 1, pp. 80–85, 2010.

[33] Y. Li, “Relationship between glucocorticoid receptor and deficiency syndrome and the regulation of traditional Chinese medicine,” *Zhong Xi Yi Jie He Xue Bao*, vol. 2, no. 3, pp. 172–174, 2004.
[34] R. Liu, P. Wang, X. Jin, Y. Wang, X. Kang, and X. Wang, “Effects of dexamethasone on hypothalamic-pituitary-adrenocortical axis and bone metabolism in rats with ovalbumin-induced asthma,” Yao Wu Bu Liang Fan Ying Za Zhi, vol. 12, no. 1, pp. 5–9, 2010.

[35] J. Dong, Z. Shi, Z. Shen et al., “Investigation of treating steroids dependent asthmatic patients with kidney-tonifying herbs and high dose beclometasone dipropionate aerosol,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 14, no. 8, pp. 458–461, 1994.

[36] G. Yang, “The curative effect of combination of Chinese traditional and Western medicine on treating mediate and severe bronchitis asthma in adults,” Zhongguo Yi Yao Ke Xue, vol. 6, no. 10, pp. 41–43, 2016.

[37] P. Demoly, M. Mathieu, J. Bousquet, F. B. Michel, and P. Godard, "Glucocorticoid receptor abnormalities in asthma," La Presse Médicale, vol. 25, no. 16, pp. 769–774, 1996.

[38] I. M. Adcock, T. Gilbey, C. M. Gelder, K. F. Chung, and P. J. Barnes, “Glucocorticoid receptor localization in normal and asthmatic lung,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 3, part 1, pp. 771–782, 1996.

[39] S. H. Korn, E. F. M. Wouters, G. Wesseling, J.-W. Arens, and F. B. J. M. Thunnissen, “In vitro and in vivo modulation of α- and β-glucocorticoid-receptor mRNA in human bronchial epithelium,” American Journal of Respiratory and Critical Care Medicine, vol. 155, no. 3, pp. 1117–1122, 1997.

[40] D. R. Dorscheid, K. R. Wojcik, S. Sun, B. Marroquin, and S. R. White, "Apoptosis of airway epithelial cells induced by corticosteroids," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, part 1, pp. 1939–1947, 2001.

[41] S. R. White and D. R. Dorscheid, "Corticosteroid-induced apoptosis of airway epithelium: a potential mechanism for chronic airway epithelial damage in asthma," Chest, vol. 122, no. 6, pp. 278S–284S, 2002.

[42] M. T. Bailey, S. G. Kinsey, D. A. Padgett, J. F. Sheridan, and B. Leblebicioglu, "Social stress enhances IL-1β and TNF-α production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells," Physiology and Behavior, vol. 98, no. 3, pp. 351–358, 2009.

[43] D. C. M. Simoes, A.-M. G. Psarra, T. Mauad et al., “Glucocorticoid and estrogen receptors are reduced in mitochondria of lung epithelial cells in asthma,” PLoS ONE, vol. 7, no. 6, Article ID e39183, 2012.

[44] Z. L. U. Nick and J. A. Cidlowski, “The origin and functions of multiple human glucocorticoid receptor isoforms,” Annals of the New York Academy of Sciences, vol. 1024, pp. 102–123, 2004.

[45] M. R. Yudt, C. M. Jewell, R. J. Bienstock, and J. A. Cidlowski, “Molecular origins for the dominant negative function of human glucocorticoid receptor beta,” Molecular and Cellular Biology, vol. 23, no. 12, pp. 4319–4330, 2003.

[46] L. Pujols, J. Mullol, and C. Picado, “Importance of glucocorticoid receptors in upper and lower airways,” Frontiers in Bioscience, vol. 15, no. 2, pp. 789–800, 2010.

[47] T. Kino, Y. A. Su, and G. P. Chrousos, “Human glucocorticoid receptor isoform β: recent understanding of its potential implications in physiology and pathophysiology,” Cellular and Molecular Life Sciences, vol. 66, no. 21, pp. 3435–3448, 2009.

[48] B. Jakiela, G. Bochenek, and M. Sanak, “Glucocorticoid receptor isoforms in steroid-dependent asthma,” Polskie Archiwum Medycyny Wewnętrznej, vol. 120, no. 6, pp. 214–222, 2010.

[49] I. J. Brogan, I. A. Murray, G. Cerillo, M. Needham, A. White, and J. R. E. Davis, “Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-κB: lack of effect of glucocorticoid receptor β,” Molecular and Cellular Endocrinology, vol. 157, no. 1-2, pp. 95–104, 1999.

[50] N. O. Vamvakopoulos, “Tissue-specific expression of heat shock proteins 70 and 90: potential implication for differential sensitivity of tissues to glucocorticoids,” Molecular and Cellular Endocrinology, vol. 98, no. 1, pp. 49–54, 1993.